Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RADIOCONTROL

Financiado

Breaching the protective cancer stroma with radiotherapy-responsive liposomes

Liposomes have been the most successful type of nanomedicine for cancer patients, playing a leading role in improving the tolerability of chemotherapeutics. However, to advance the success of liposomal drug delivery and cancer tre... ver más

31/03/2028

INSERM

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-02-08

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-STG: ERC STARTING GRANTS

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

INSERM

1.94M€ | Lider

Proyectos interesantes

PDC2022-133036-I00 NANOABRICACION ESCALADA DE NANOCAPSULAS MAGNETOPLASMONICAS P... 150K€ Cerrado

PCIN-2017-042 NANOTRANSPORTADORES POLIPEPTIDICOS SENSIBLES A LA TEMPERATUR... 138K€ Cerrado

RTI2018-098164-B-I00 MOVIMIENTO DE NANOROBOTS BIOCATALITICOS EN FLUIDOS BIOLOGICO... 218K€ Cerrado

CTQ2017-89588-R NANOCAPSULAS BIOMIMETICAS PARA LA ADMINISTRACION DIRIGIDA DE... 71K€ Cerrado

DEXTER Development of EXtracellular-based artificial bio-nanopartic... 181K€ Cerrado

MAT2016-78201-P LIBERACION DE FARMACOS MEDIANTE NANOVECTORES TERMOSENSIBLES... 97K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 61 meses Fecha Inicio: 2023-02-08
Fecha Fin: 2028-03-31

Presupuesto del proyecto 2M€

Descripción del proyecto Liposomes have been the most successful type of nanomedicine for cancer patients, playing a leading role in improving the tolerability of chemotherapeutics. However, to advance the success of liposomal drug delivery and cancer treatment, new approaches to physically trigger drug release in cancer tissues and increase the permeability of the protective cancer stroma are needed. This project will investigate whether radiocatalytic nanomaterials can be integrated in liposomes for spatiotemporal-controlled drug release, the alleviation of cancer desmoplasia, and improved efficacy of co-encapsulated drugs. Liposomes will be composed of oxidation-susceptible phospholipids that encapsulate hydrophilic drugs in their aqueous core. Radiation-absorbing nanomaterials will be included in the liposomes to produce high levels of reactive oxygen species when activated by X-rays. This will oxidize the liposomes and facilitate the release of the encapsulated drugs. Simultaneously, the cytotoxicity of the oxidants is expected to reduce the high cell densities in the tumor periphery, enabling the therapeutics to deeply permeate the cancer tissues following their release. This customizable strategy will be developed in the context of pancreatic cancer, a chemoresistant form of cancer with poor survival rates. This project develops a multidisciplinary approach to investigate the physicochemical mechanisms of radiotherapy-induced drug release, adaptive optics microscopy to study tissue permeability in 3D cultures of desmoplastic pancreatic cancer, and multimodal in vivo imaging to uncover the therapeutic potential and mechanisms. Radiotherapy-controlled drug release from liposomes is a ground-breaking novel concept, and its capacity to increase cancer tissue permeability has never before been demonstrated. When successful, new avenues for controlled liposomal drug delivery will emerge that can significantly advance the standard-of-care for many cancer patients.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores